


## PHARMACEUTICAL 2022

## Rain Therapeutics Inc. Rank 218 of 475





## PHARMACEUTICAL 2022

## Rain Therapeutics Inc. Rank 218 of 475

The relative strengths and weaknesses of Rain Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rain Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 210% points. The greatest weakness of Rain Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is -80%, being 197% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	146,146
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,315
Liabilities, Non-Current	321
Other Assets	829
Other Compr. Net Income	-89
Other Expenses	2.0
Other Liabilities	0
Other Net Income	120
Property and Equipment	165
Research and Development	40,773
Revenues	0
Selling, General and Administrative Expense	10,739

Output Variable	Value in 1000 USD
Assets	147,140
Liabilities	16,636
Expenses	51,514
Stockholders Equity	130,504
Net Income	-51,394
Comprehensive Net Income	-51,438
Economic Capital Ratio	-80%